Article in Journal of neurophysiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
8 authors.
Viktor YarotskyyDepartment of Pharmacology and Toxicology, School of Medicine, Virginia Commonwealth University, Richmond, Virginia, United States.ORCID 0000-0002-9247-6975
Rachel M SchmittDepartment of Pharmacology and Toxicology, School of Medicine, Virginia Commonwealth University, Richmond, Virginia, United States.ORCID 0009-0003-8610-2330
Hannah J GoudswardDepartment of Pharmacology and Toxicology, School of Medicine, Virginia Commonwealth University, Richmond, Virginia, United States.ORCID 0000-0003-4417-7206
Sara R NassDepartment of Pharmacology and Toxicology, School of Medicine, Virginia Commonwealth University, Richmond, Virginia, United States.ORCID 0000-0003-1868-1257
Kyle HarbourDepartment of Pharmacology and Toxicology, School of Medicine, Virginia Commonwealth University, Richmond, Virginia, United States.ORCID 0000-0003-1763-8265
A Rory McQuistonDepartment of Neuroscience and Anatomy, School of Medicine, Virginia Commonwealth University, Richmond, Virginia, United States.ORCID 0000-0003-3338-367X
Pamela E KnappDepartment of Pharmacology and Toxicology, School of Medicine, Virginia Commonwealth University, Richmond, Virginia, United States.ORCID 0000-0003-4364-6074
Kurt F HauserDepartment of Pharmacology and Toxicology, School of Medicine, Virginia Commonwealth University, Richmond, Virginia, United States.ORCID 0000-0001-7886-0332
Funding
Innovative therapeutic approaches to address excitotoxic CNS/neuronal damage in opioid-neuroHIV comorbidityR01DA057346 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI Kurt F Hauser, Pamela E Knapp · 2022 to 2026
$3.4M
Selective vulnerability of discrete neural circuits in the striatum to HIV-opiate comorbidityR01DA045588 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI HAUSER, KURT F · 2018 to 2022
$2.0M
Opioid and non-opioid receptor mechanisms in neurons and glia underlying fentanyl and HIV comorbidity in the striatumR01DA060724 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI Kurt F Hauser, Viktor Yarotskyy · 2024 to 2026
$2.0M
Chloride channel-dependent mechanisms of opiate and HIV-induced synaptodendritic injuryR21DA057153 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI HAUSER, KURT F, YAROTSKYY, VIKTOR · 2022 to 2023
$427k
The influence of astroglial mu opioid receptors in opioid potentiation of HIV neuropathogenesisK99DA059324 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI NASS, SARA · 2024 to 2025
$374k
HIV and opiate interactions in behavioral and anterior cingulate cortex synaptic dysfunctionF32DA053163 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI NASS, SARA · 2021 to 2022
$140k
HHS | NIH | National Institute on Drug Abuse (NIDA) DA060724NIDA NIH HHS F32 DA053163NIDA NIH HHS K99 DA059324NIDA NIH HHS R01 DA045588NIDA NIH HHS R01 DA057346NIDA NIH HHS R01 DA060724NIDA NIH HHS R21 DA057153
6 · The paper itself
Abstract
Co-exposure to fentanyl, a μ-opioid receptor (MOR) agonist, and xylazine, a pan-α
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Acute fentanyl and xylazine co-exposure uniquely increase the excitability of dopamine type 2 receptor-expressing striatal medium spiny neurons. · full record | OpenQuestion